Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT Extension study of daclizumab HYP in relapsing-remitting multiple sclerosis
2008-005559-46Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of daclizumab in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Safety and Immunogenicity. Started Nov 2008; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-005559-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005559-46.